Stock Events

Liquidia 

$13.29
50
-$0.52-3.77% Friday 20:00

Statistics

Day High
13.97
Day Low
12.85
52W High
16.99
52W Low
5.71
Volume
829,398
Avg. Volume
849,204
Mkt Cap
1.01B
P/E Ratio
-10.98
Dividend Yield
-
Dividend
-

Upcoming

Earnings

2MayExpected
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Next
-0.36
-0.24
-0.12
0
Expected EPS
-0.31
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow LQDA. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Innoviva
INVA
Mkt Cap945.25M
Innoviva focuses on the development and commercialization of pharmaceuticals, directly competing in the respiratory and pulmonary market similar to Liquidia's focus.
Vertex Pharmaceuticals
VRTX
Mkt Cap101.91B
Vertex Pharmaceuticals is involved in creating therapies for cystic fibrosis, a direct competition to Liquidia's pulmonary disease treatments.
GSK
GSK
Mkt Cap82.38B
GlaxoSmithKline produces a wide range of pharmaceuticals, including treatments for respiratory diseases, directly competing with Liquidia's product offerings.
Astrazeneca
AZN
Mkt Cap212.54B
AstraZeneca is a global biopharmaceutical company focusing on various therapeutic areas, including respiratory diseases, making it a competitor to Liquidia.
Merck &
MRK
Mkt Cap318.6B
Merck & Co., Inc. offers a broad portfolio of drugs, including treatments for respiratory conditions, competing in the same space as Liquidia.
Pfizer
PFE
Mkt Cap147.23B
Pfizer develops and manufactures drugs and vaccines, including for respiratory diseases, positioning it as a competitor to Liquidia.
Biogen
BIIB
Mkt Cap28.26B
Biogen focuses on advanced therapies for serious diseases, including pulmonary conditions, making it a competitor in the same therapeutic area as Liquidia.
Regeneron Pharmaceuticals
REGN
Mkt Cap96.81B
Regeneron Pharmaceuticals is known for its innovative treatments in several areas, including respiratory diseases, competing with Liquidia's developments.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap14.42B
Teva Pharmaceutical Industries specializes in generic and specialty medicines, including for respiratory conditions, making it a competitor to Liquidia.
Novartis
NVS
Mkt Cap206.64B
Novartis focuses on a wide range of healthcare areas, including respiratory diseases, directly competing with Liquidia's therapeutic focus.

Analyst Ratings

21.6$Average Price Target
The highest estimate is $32.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
80%
Hold
0%
Sell
20%

About

Health Technology
Pharmaceuticals: Major
Manufacturing
Medicinal and Botanical Manufacturing
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
Show more...
CEO
Neal Fowler
Employees
145
Country
US
ISIN
US53635D2027
WKN
000A2JRNS

Listings